Pulse Biosciences (NASDAQ:PLSE) Cut to “Strong Sell” at BidaskClub

BidaskClub lowered shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a strong sell rating in a research report released on Tuesday morning, BidAskClub reports.

PLSE has been the topic of a number of other research reports. HC Wainwright reaffirmed a buy rating on shares of Pulse Biosciences in a report on Wednesday, May 1st. ValuEngine raised shares of Whiting Petroleum from a strong sell rating to a sell rating in a report on Friday, April 5th.

Shares of PLSE stock traded down $0.27 during trading hours on Tuesday, reaching $12.42. The stock had a trading volume of 2,034 shares, compared to its average volume of 38,175. The company has a quick ratio of 17.13, a current ratio of 17.13 and a debt-to-equity ratio of 0.02. Pulse Biosciences has a twelve month low of $8.60 and a twelve month high of $19.77. The company’s 50-day simple moving average is $12.39. The company has a market cap of $260.33 million, a price-to-earnings ratio of -5.65 and a beta of 1.79.



Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). Analysts predict that Pulse Biosciences will post -2.09 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its stake in Pulse Biosciences by 10.2% during the 4th quarter. Northern Trust Corp now owns 121,031 shares of the company’s stock valued at $1,387,000 after buying an additional 11,212 shares during the period. Geode Capital Management LLC increased its stake in Pulse Biosciences by 49.5% during the 4th quarter. Geode Capital Management LLC now owns 117,149 shares of the company’s stock valued at $1,342,000 after buying an additional 38,763 shares during the period. Griffin Asset Management Inc. acquired a new position in Pulse Biosciences during the 1st quarter valued at about $903,000. Rhumbline Advisers acquired a new position in Pulse Biosciences during the 4th quarter valued at about $159,000. Finally, BNP Paribas Arbitrage SA increased its stake in Pulse Biosciences by 1,082.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,259 shares of the company’s stock valued at $40,000 after buying an additional 2,068 shares during the period. 9.09% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

See Also: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.